Detour2 Continued Access Study

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

May 14, 2024

Study Completion Date

May 14, 2024

Conditions
Peripheral Artery Diseases
Interventions
DEVICE

PQ Bypass System

Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.

Trial Locations (3)

23502

Sentara Norfolk, Norfolk

60007

AMITA Medical Group, Elk Grove Village

06475

The Vascular Experts, Old Saybrook

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Endologix

INDUSTRY

NCT04625660 - Detour2 Continued Access Study | Biotech Hunter | Biotech Hunter